Review





Similar Products

vsmcs  (MedChemExpress)
95
MedChemExpress vsmcs
E2F transcription factor 5 (E2F5) knockdown repressed vascular smooth muscle cells <t>(VSMCs)</t> phenotype switching through inactivating Wnt/β-catenin pathway. (A) Western blot for detecting wnt1 and β-catenin expression in VSMCs in different groups. (B) 5-ethynyl-2´-deoxyuridine (EdU) assay was employed for assessing the proliferative ability of VSMCs (×200). (C) Flow cytometry was employed for testing VSMCs cell cycle. (D) Transwell assay was utilized for evaluating the migrative ability of VSMCs (×100). (E) Western blot for detecting α-smooth muscle actin (α-SMA), SM22, and osteopontin (OPN) expression in VSMCs. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HG, high glucose; ox-LDL, oxidized low-density lipoprotein; si-NC, negative control <t>siRNA;</t> <t>BML-284,</t> a Wnt pathway activator; DAPI, 4´,6-diamidino-2-phenylindole. a P <0.05, b P <0.05, c P <0.05.
Vsmcs, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bml-284/pmc13175694-61-1-10?v=MedChemExpress
Average 95 stars, based on 1 article reviews
vsmcs - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier
bml 284  (TargetMol)
94
TargetMol bml 284
E2F transcription factor 5 (E2F5) knockdown repressed vascular smooth muscle cells <t>(VSMCs)</t> phenotype switching through inactivating Wnt/β-catenin pathway. (A) Western blot for detecting wnt1 and β-catenin expression in VSMCs in different groups. (B) 5-ethynyl-2´-deoxyuridine (EdU) assay was employed for assessing the proliferative ability of VSMCs (×200). (C) Flow cytometry was employed for testing VSMCs cell cycle. (D) Transwell assay was utilized for evaluating the migrative ability of VSMCs (×100). (E) Western blot for detecting α-smooth muscle actin (α-SMA), SM22, and osteopontin (OPN) expression in VSMCs. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HG, high glucose; ox-LDL, oxidized low-density lipoprotein; si-NC, negative control <t>siRNA;</t> <t>BML-284,</t> a Wnt pathway activator; DAPI, 4´,6-diamidino-2-phenylindole. a P <0.05, b P <0.05, c P <0.05.
Bml 284, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bml-284/pm41674366-231-23-24?v=TargetMol
Average 94 stars, based on 1 article reviews
bml 284 - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier
bml 284  (MedChemExpress)
95
MedChemExpress bml 284
E2F transcription factor 5 (E2F5) knockdown repressed vascular smooth muscle cells <t>(VSMCs)</t> phenotype switching through inactivating Wnt/β-catenin pathway. (A) Western blot for detecting wnt1 and β-catenin expression in VSMCs in different groups. (B) 5-ethynyl-2´-deoxyuridine (EdU) assay was employed for assessing the proliferative ability of VSMCs (×200). (C) Flow cytometry was employed for testing VSMCs cell cycle. (D) Transwell assay was utilized for evaluating the migrative ability of VSMCs (×100). (E) Western blot for detecting α-smooth muscle actin (α-SMA), SM22, and osteopontin (OPN) expression in VSMCs. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HG, high glucose; ox-LDL, oxidized low-density lipoprotein; si-NC, negative control <t>siRNA;</t> <t>BML-284,</t> a Wnt pathway activator; DAPI, 4´,6-diamidino-2-phenylindole. a P <0.05, b P <0.05, c P <0.05.
Bml 284, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bml-284/10__1016_slash_j__jes__2026__05__021-74-0-10?v=MedChemExpress
Average 95 stars, based on 1 article reviews
bml 284 - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier
wnt agonist bml 284  (Selleck Chemicals)
93
Selleck Chemicals wnt agonist bml 284
E2F transcription factor 5 (E2F5) knockdown repressed vascular smooth muscle cells <t>(VSMCs)</t> phenotype switching through inactivating Wnt/β-catenin pathway. (A) Western blot for detecting wnt1 and β-catenin expression in VSMCs in different groups. (B) 5-ethynyl-2´-deoxyuridine (EdU) assay was employed for assessing the proliferative ability of VSMCs (×200). (C) Flow cytometry was employed for testing VSMCs cell cycle. (D) Transwell assay was utilized for evaluating the migrative ability of VSMCs (×100). (E) Western blot for detecting α-smooth muscle actin (α-SMA), SM22, and osteopontin (OPN) expression in VSMCs. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HG, high glucose; ox-LDL, oxidized low-density lipoprotein; si-NC, negative control <t>siRNA;</t> <t>BML-284,</t> a Wnt pathway activator; DAPI, 4´,6-diamidino-2-phenylindole. a P <0.05, b P <0.05, c P <0.05.
Wnt Agonist Bml 284, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bml-284/pmc12977471-42-14-17?v=Selleck+Chemicals
Average 93 stars, based on 1 article reviews
wnt agonist bml 284 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
hrecs  (MedChemExpress)
95
MedChemExpress hrecs
E2F transcription factor 5 (E2F5) knockdown repressed vascular smooth muscle cells <t>(VSMCs)</t> phenotype switching through inactivating Wnt/β-catenin pathway. (A) Western blot for detecting wnt1 and β-catenin expression in VSMCs in different groups. (B) 5-ethynyl-2´-deoxyuridine (EdU) assay was employed for assessing the proliferative ability of VSMCs (×200). (C) Flow cytometry was employed for testing VSMCs cell cycle. (D) Transwell assay was utilized for evaluating the migrative ability of VSMCs (×100). (E) Western blot for detecting α-smooth muscle actin (α-SMA), SM22, and osteopontin (OPN) expression in VSMCs. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HG, high glucose; ox-LDL, oxidized low-density lipoprotein; si-NC, negative control <t>siRNA;</t> <t>BML-284,</t> a Wnt pathway activator; DAPI, 4´,6-diamidino-2-phenylindole. a P <0.05, b P <0.05, c P <0.05.
Hrecs, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bml-284/pm41638389-104-3-16?v=MedChemExpress
Average 95 stars, based on 1 article reviews
hrecs - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier
wnt β catenin signaling pathway agonist bml 284  (MedChemExpress)
95
MedChemExpress wnt β catenin signaling pathway agonist bml 284
E2F transcription factor 5 (E2F5) knockdown repressed vascular smooth muscle cells <t>(VSMCs)</t> phenotype switching through inactivating Wnt/β-catenin pathway. (A) Western blot for detecting wnt1 and β-catenin expression in VSMCs in different groups. (B) 5-ethynyl-2´-deoxyuridine (EdU) assay was employed for assessing the proliferative ability of VSMCs (×200). (C) Flow cytometry was employed for testing VSMCs cell cycle. (D) Transwell assay was utilized for evaluating the migrative ability of VSMCs (×100). (E) Western blot for detecting α-smooth muscle actin (α-SMA), SM22, and osteopontin (OPN) expression in VSMCs. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HG, high glucose; ox-LDL, oxidized low-density lipoprotein; si-NC, negative control <t>siRNA;</t> <t>BML-284,</t> a Wnt pathway activator; DAPI, 4´,6-diamidino-2-phenylindole. a P <0.05, b P <0.05, c P <0.05.
Wnt β Catenin Signaling Pathway Agonist Bml 284, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bml-284/pm41574400-55-15-21?v=MedChemExpress
Average 95 stars, based on 1 article reviews
wnt β catenin signaling pathway agonist bml 284 - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier
bml 284 hy19987  (MedChemExpress)
95
MedChemExpress bml 284 hy19987
E2F transcription factor 5 (E2F5) knockdown repressed vascular smooth muscle cells <t>(VSMCs)</t> phenotype switching through inactivating Wnt/β-catenin pathway. (A) Western blot for detecting wnt1 and β-catenin expression in VSMCs in different groups. (B) 5-ethynyl-2´-deoxyuridine (EdU) assay was employed for assessing the proliferative ability of VSMCs (×200). (C) Flow cytometry was employed for testing VSMCs cell cycle. (D) Transwell assay was utilized for evaluating the migrative ability of VSMCs (×100). (E) Western blot for detecting α-smooth muscle actin (α-SMA), SM22, and osteopontin (OPN) expression in VSMCs. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HG, high glucose; ox-LDL, oxidized low-density lipoprotein; si-NC, negative control <t>siRNA;</t> <t>BML-284,</t> a Wnt pathway activator; DAPI, 4´,6-diamidino-2-phenylindole. a P <0.05, b P <0.05, c P <0.05.
Bml 284 Hy19987, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bml-284/pm41534557-49-5-10?v=MedChemExpress
Average 95 stars, based on 1 article reviews
bml 284 hy19987 - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier
wnt β catenin signaling pathways activator bml284  (MedChemExpress)
95
MedChemExpress wnt β catenin signaling pathways activator bml284
E2F transcription factor 5 (E2F5) knockdown repressed vascular smooth muscle cells <t>(VSMCs)</t> phenotype switching through inactivating Wnt/β-catenin pathway. (A) Western blot for detecting wnt1 and β-catenin expression in VSMCs in different groups. (B) 5-ethynyl-2´-deoxyuridine (EdU) assay was employed for assessing the proliferative ability of VSMCs (×200). (C) Flow cytometry was employed for testing VSMCs cell cycle. (D) Transwell assay was utilized for evaluating the migrative ability of VSMCs (×100). (E) Western blot for detecting α-smooth muscle actin (α-SMA), SM22, and osteopontin (OPN) expression in VSMCs. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HG, high glucose; ox-LDL, oxidized low-density lipoprotein; si-NC, negative control <t>siRNA;</t> <t>BML-284,</t> a Wnt pathway activator; DAPI, 4´,6-diamidino-2-phenylindole. a P <0.05, b P <0.05, c P <0.05.
Wnt β Catenin Signaling Pathways Activator Bml284, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bml-284/pm41486849-340-23-30?v=MedChemExpress
Average 95 stars, based on 1 article reviews
wnt β catenin signaling pathways activator bml284 - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier

Image Search Results


E2F transcription factor 5 (E2F5) knockdown repressed vascular smooth muscle cells (VSMCs) phenotype switching through inactivating Wnt/β-catenin pathway. (A) Western blot for detecting wnt1 and β-catenin expression in VSMCs in different groups. (B) 5-ethynyl-2´-deoxyuridine (EdU) assay was employed for assessing the proliferative ability of VSMCs (×200). (C) Flow cytometry was employed for testing VSMCs cell cycle. (D) Transwell assay was utilized for evaluating the migrative ability of VSMCs (×100). (E) Western blot for detecting α-smooth muscle actin (α-SMA), SM22, and osteopontin (OPN) expression in VSMCs. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HG, high glucose; ox-LDL, oxidized low-density lipoprotein; si-NC, negative control siRNA; BML-284, a Wnt pathway activator; DAPI, 4´,6-diamidino-2-phenylindole. a P <0.05, b P <0.05, c P <0.05.

Journal: Diabetes & Metabolism Journal

Article Title: E2F5 Accelerates Vascular Smooth Muscle Cells Phenotype Switching in Diabetic Atherosclerosis through Activating Wnt/β-Catenin Pathway

doi: 10.4093/dmj.2024.0588

Figure Lengend Snippet: E2F transcription factor 5 (E2F5) knockdown repressed vascular smooth muscle cells (VSMCs) phenotype switching through inactivating Wnt/β-catenin pathway. (A) Western blot for detecting wnt1 and β-catenin expression in VSMCs in different groups. (B) 5-ethynyl-2´-deoxyuridine (EdU) assay was employed for assessing the proliferative ability of VSMCs (×200). (C) Flow cytometry was employed for testing VSMCs cell cycle. (D) Transwell assay was utilized for evaluating the migrative ability of VSMCs (×100). (E) Western blot for detecting α-smooth muscle actin (α-SMA), SM22, and osteopontin (OPN) expression in VSMCs. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HG, high glucose; ox-LDL, oxidized low-density lipoprotein; si-NC, negative control siRNA; BML-284, a Wnt pathway activator; DAPI, 4´,6-diamidino-2-phenylindole. a P <0.05, b P <0.05, c P <0.05.

Article Snippet: Meanwhile, VSMCs were treated with BML-284 (a Wnt pathway activator, Med-ChemExpress, Monmouth Junction, NJ, USA) for 48 hours.

Techniques: Knockdown, Western Blot, Expressing, EdU Assay, Flow Cytometry, Transwell Assay, Negative Control